Cancer drugmaker Plexxikon gets new life as Opna Bio

A shuttered biotechnology company’s research is getting a second chance months after parent corporation Daiichi Sankyo closed down the cancer drug developer.

Opna Bio, which emerged from stealth Monday with former Plexxikon CEO Gideon Bollag at the helm, will develop Plexxikon’s drugs in tandem with a new program built around technology developed by a Swiss research institute.